clinical trial · NCT00353496
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Ipsen·phase3·completed·n = 264
Endocrine Tumorslanreotide (Autogel formulation)Placebo
brief summary
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
started
Jun 1, 2006
primary completion
Apr 1, 2013
completion
Apr 1, 2013
last updated
Mar 5, 2025
official title
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol